Analytical Data
-
Gene name
GNb1
- Application
-
Alternative Names
GN-B1; Guanine Nucleotide Binding Protein Beta 1; Transducin beta chain 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P62873
-
Expression Region
Ser2~Asn340
-
Molecular Weight
44kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The GNb1 protein has garnered significant attention in the field of biochemistry and molecular biology due to its potential therapeutic applications and its role in various physiological processes. Research indicates that GNb1 is involved in modulating immune responses and may play a critical role in neuroprotection, making it a candidate for studying autoimmune diseases and neurodegenerative disorders. Initial studies have demonstrated that GNb1 functions as a receptor agonist, influencing signaling pathways that regulate inflammation and cell survival. Moreover, its ability to bind to specific cellular targets suggests that it may act as a biomarker or therapeutic agent in clinical settings. The recombinant production of GNb1 has facilitated in-depth investigations into its structural properties, functional mechanisms, and potential for drug development. Advanced techniques, such as CRISPR gene editing and protein engineering, have been employed to optimize the yield and activity of the recombinant protein, paving the way for high-throughput screening of its biological effects. As researchers continue to elucidate the diverse roles of GNb1, understanding its modulation could lead to novel strategies for treating diseases where inflammatory processes are disrupted. The ongoing exploration of GNb1's potential underscores the importance of comprehensive studies in recombinant protein research, highlighting the protein's significance in therapeutic innovations and the broader implications for health and disease management.
